Literature DB >> 19481569

Protease-activated receptors as drug targets in inflammation and pain.

Nathalie Vergnolle1.   

Abstract

Proteases have been shown to signal to cells through the activation of a novel class of receptors coupled to G proteins: the protease-activated receptors (PARs). Those receptors are expressed in a wide range of cells, which ultimately are all involved in mechanisms of inflammation and pain. Numerous studies have considered the role of PARs in cells, organ systems or in vivo, highlighting the fact that PAR activation results in signs of inflammation. A growing body of evidences discussed here suggests that these receptors, and the proteases that activate them, interfere with inflammation and pain processes. Whether a role for PARs has been clearly defined in inflammatory and pain pathologies is discussed in this review. Further, the pros and cons for considering PARs as targets for the development of therapeutic options for the treatment of inflammation and pain are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481569     DOI: 10.1016/j.pharmthera.2009.05.004

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  48 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Neutrophil Elastase Activates Protease-activated Receptor-2 (PAR2) and Transient Receptor Potential Vanilloid 4 (TRPV4) to Cause Inflammation and Pain.

Authors:  Peishen Zhao; TinaMarie Lieu; Nicholas Barlow; Silvia Sostegni; Silke Haerteis; Christoph Korbmacher; Wolfgang Liedtke; Nestor N Jimenez-Vargas; Stephen J Vanner; Nigel W Bunnett
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

4.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

5.  Protease-activated receptors as therapeutic targets in visceral pain.

Authors:  Nicolas Cenac
Journal:  Curr Neuropharmacol       Date:  2013-12       Impact factor: 7.363

Review 6.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

Review 7.  Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection.

Authors:  M D Hollenberg
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

8.  Role of enteric nerves in immune-mediated changes in protease-activated receptor 2 effects on gut function.

Authors:  T Shea-Donohue; L Notari; J Stiltz; R Sun; K B Madden; J F Urban; A Zhao
Journal:  Neurogastroenterol Motil       Date:  2010-07-11       Impact factor: 3.598

9.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 10.  Neuroanatomy of lower gastrointestinal pain disorders.

Authors:  Wim Vermeulen; Joris G De Man; Paul A Pelckmans; Benedicte Y De Winter
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.